Tarsus Pharmaceuticals Stock Investor Sentiment

TARS Stock  USD 48.24  1.84  3.97%   
Slightly above 56% of Tarsus Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Tarsus Pharmaceuticals stock suggests that many investors are alarmed at this time. Tarsus Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Tarsus Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  

Tarsus Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Tarsus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
3 days ago at news.google.com         
Mutual of America Capital Management LLC Invests 4.29 Million in Tarsus Pharmaceuticals, Inc. - Mark...
Google News at Macroaxis
few days ago at news.google.com         
Tarsus Pharmaceuticals, Inc. Expected to Beat Earnings Estimates Can the Stock Move Higher - MSN
Google News at Macroaxis
six days ago at zacks.com         
Wall Street Analysts Believe Tarsus Pharmaceuticals Could Rally 41.09 percent Heres is How to Trade
zacks News
six days ago at finance.yahoo.com         
Wall Street Analysts Believe Tarsus Pharmaceuticals Could Rally 41.09 percent Heres is How to Trade
Yahoo News
over a week ago at simplywall.st         
US65.33 - Thats What Analysts Think Tarsus Pharmaceuticals, Inc. Is Worth After These Results
Simply Wall St News at Macroaxis
over a week ago at investing.com         
Tarsus Pharmaceuticals stock target upgraded, holds buy on strong sales
Investing News at Macroaxis
over a week ago at simplywall.st         
Tarsus Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over a week ago at insidermonkey.com         
Tarsus Pharmaceuticals, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over a week ago at gurufocus.com         
Tarsus Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Record Sales and Strategic ...
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Jennison Associates LLC Increases Stake in Tarsus Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over a week ago at zacks.com         
Insider Trading
zacks News
over a week ago at gurufocus.com         
Tarsus Pharmaceuticals Inc Q3 2024 Earnings EPS of 0. ...
Gurufocus Stories at Macroaxis
over a week ago at seekingalpha.com         
Tarsus Pharmaceuticals GAAP EPS of -0.61 beats by 0.31, revenue of 48.1M beats by 4.92M
seekingalpha News
over a week ago at zacks.com         
2seventy bio, Inc. Reports Q3 Loss, Lags Revenue Estimates
zacks News
over two weeks ago at simplywall.st         
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.s Prospects As Shares Rocket 41
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Tarsus Pharmaceuticals that are available to investors today. That information is available publicly through Tarsus media outlets and privately through word of mouth or via Tarsus internal channels. However, regardless of the origin, that massive amount of Tarsus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tarsus Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tarsus Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tarsus Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tarsus Pharmaceuticals alpha.

Tarsus Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Link William J Phd of 27116 shares of Tarsus Pharmaceuticals subject to Rule 16b-3
08/30/2024
2
Disposition of 1333 shares by Morrison Scott W of Tarsus Pharmaceuticals subject to Rule 16b-3
09/13/2024
3
Tarsus Pharmaceuticals, Inc.s Path To Profitability
10/09/2024
4
Head to Head Survey Tarsus Pharmaceuticals and Voyager Therapeutics
10/15/2024
5
Amicus Therapeutics Stock Jumps 14.0 percent Will It Continue to Soar
10/18/2024
6
Acquisition by Yarno Wendy L of 3350 shares of Tarsus Pharmaceuticals subject to Rule 16b-3
10/28/2024
7
Acquisition by Lin Elizabeth Yeu of 27278 shares of Tarsus Pharmaceuticals subject to Rule 16b-3
11/04/2024
8
Vanguard Group Incs Strategic Acquisition in Tarsus Pharmaceuticals Inc
11/05/2024
9
2seventy bio, Inc. Reports Q3 Loss, Lags Revenue Estimates
11/12/2024
10
Tarsus Pharmaceuticals GAAP EPS of -0.61 beats by 0.31, revenue of 48.1M beats by 4.92M
11/13/2024
11
Tarsus Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations
11/15/2024
12
Mutual of America Capital Management LLC Invests 4.29 Million in Tarsus Pharmaceuticals, Inc. - MarketBeat
11/22/2024

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.